Induction of antitumor resistance to mouse leukemia L1210 by spergualins.
Spergualin and its analog, 15-deoxyspergualin showed a marked antitumor effect against L1210 by intraperitoneal and oral administrations. After treatment with these substances 40- or 60-day survivors (cured mice of L1210) were resistant to reinoculation of L1210 cells. They were resistant only to L1210. The antitumor effector cells in these mice were determined to be T cells. NK activity of spleen cells was also enhanced by spergualins. The antitumor activity of 15-deoxyspergualin was markedly reduced in immuno-deficient mice. IL (interleukin)-2 production, but not IL-1, was enhanced in supernatant of mixed lymphocyte cultures by treatment with 15-deoxyspergualin. The mechanism of action of 15-deoxyspergualin on the immune system was discussed.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D001688:Biological Products / Q000096:biosynthesis; D016207:Cytokines; D006146:Guanidines / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D007939:Leukemia L1210 / Q000188:drug therapy / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology
D000903:Antibiotics, Antineoplastic; D001688:Biological Products; D016207:Cytokines; D006146:Guanidines; D007166:Immunosuppressive Agents; C033797:spergualin; C037258:gusperimus